Gastrointestinal Cancer | Specialty

The OncLive Gastrointestinal Cancer condition center page is a comprehensive resource for clinical news and expert insights on various types of gastrointestinal (GI) cancers, including hepatocellular carcinoma, gastric cancer, pancreatic cancer, colorectal cancer, cholangiocarcinoma, esophageal cancer, and more. This page features news articles, interviews in written and video format, and podcasts that focus on unmet needs, treatment advances, and ongoing research in GI cancers.

Bevacizumab Plus Second-Line Chemotherapy Extends Survival in Advanced Colorectal Cancer Patients

June 3rd 2012

Bevacizumab plus chemotherapy as a second-line treatment for metastatic colorectal cancer improved survival among patients whose disease had progressed after first-line combination therapy with bevacizumab.

Surgery for Colorectal Cancer Hepatic Metastases Has Little Effect on Health

May 25th 2012

Liver surgery for colorectal cancer hepatic metastases has, for the most part, a minimal and brief negative impact on patient-reported outcomes.

NCCN 17th Annual Conference: Clinical Practice Guidelines & Quality Cancer Care

May 23rd 2012

At this year's annual NCCN conference, the organization presented updates in 13 areas, including specific disease states and general screening methods.

Colonoscopy Recommendation May Cut Adherence to CRC Screening

May 18th 2012

Patients are less likely to complete colorectal cancer screening if their physician recommended colonoscopy rather than recommending fecal occult blood testing.

May 2012: Trials in Progress

May 14th 2012

The Trials in Progress section supplies summaries of ongoing research in a broad range of cancer types.

All Patients With Colorectal Cancer Should Be Genetically Screened

May 7th 2012

Universal tumor testing and a detailed personal and family history assessment are recommended for all patients with newly diagnosed colorectal cancer.

Brivanib Plus Cetuximab Delivers Mixed Results in Colorectal Study

April 16th 2012

Adding brivanib alaninate to cetuximab had no survival advantage over cetuximab alone in patients with KRAS wild-type chemorefractory metastatic colorectal cancer.

Research Backs Anti-EGFR Therapy in mCRC With Wild-Type KRAS

April 13th 2012

New research on predictive and prognostic biomarkers for therapy targeting EGFR strongly suggests that panitumumab should be reserved for mCRC tumors with wild-type KRAS.

Addition of Oxaliplatin to Adjuvant Therapy for Late-Stage Colon Cancer Shows Benefit in Real-World Setting

April 13th 2012

Adding oxaliplatin to conventional chemotherapy increases survival in patients with advanced colon cancer in a broad range of community practice settings.

Optical Biomarkers Distinguish Risk Levels in Barrett's Esophagus

April 12th 2012

Optical biomarkers derived from nondysplastic metaplastic cells can detect the presence of high-grade dysplasia and adenocarcinoma from Barrett's esophagus.

Many Patients Continue to Smoke After Cancer Diagnosis

April 11th 2012

Being newly diagnosed with lung or colorectal cancer is often not sufficient to motivate cigarette smokers to quit.

Prognostic Factors for Progression of Neuroendocrine Tumors Identified in Reanalysis of RADIANT-2

April 5th 2012

The addition of everolimus to standard octreotide LAR achieved about a 5-month improvement in progression-free survival in patients with advanced neuroendocrine tumors.

Adjuvant Cetuximab Fails to Improve Survival in Colon Cancer

April 3rd 2012

Patients who received cetuximab in combination with a standard adjuvant therapy treatment for colon cancer did not experience improved survival.

Serum-Based Protein Immunoassay Can Detect Early Pancreatic Cancer

April 2nd 2012

An immunoassay to detect the presence of PAM4 showed promise for the detection and diagnosis of early-stage pancreatic ductal adenocarcinoma.

More Research Needed to Define Appropriate Targets for Biologic Therapy of Gastric Cancer

March 30th 2012

More research is needed to define molecular subtypes of gastric cancer and identify appropriate targets for clinical use.

Regorafenib Potential Treatment for Metastatic Colorectal Cancer Failing Standard Treatment Options

March 28th 2012

For patients with metastatic colorectal cancer that has progressed on multiple lines of standard therapy, regorafenib may be a new treatment option that achieves disease control.

Prediagnostic Obesity Curbs Colorectal Cancer Survival

March 27th 2012

Patients who are obese before being diagnosed with colorectal cancer are more likely to die of their disease than patients who are at a normal weight prediagnosis.

Tivantinib Extends Time to Progression in HCC Patients

March 19th 2012

Treatment with tivantinib produced a 56% improvement in time-to-progression in patients with hepatocellular carcinoma.

Everolimus Plus Octreotide LAR Is Effective in Advanced Neuroendocrine Tumors

March 8th 2012

Combination therapy with everolimus and the octreotide LAR increases the median PFS in patients with advanced neuroendocrine tumors associated with carcinoid syndrome.

Baseline Glucose Levels in Older Women May Be Linked to Colorectal Cancer Risk

February 29th 2012

New findings suggest that increased serum glucose levels may be a risk factor for colorectal cancer in postmenopausal women.